RXRX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 427 min ago

@ $8.61

Wydano: 9 geg. 2024 @ 21:39

Zwrot: 0.35%

Poprzedni sygnał: geg. 9 - 21:16

Poprzedni sygnał: Kupno

Zwrot: 0.76 %

Live Chart Being Loaded With Signals

Commentary (9 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	2.72M
Średni wolumen	6.45M
Kapitalizacja rynkowa	1.99B
EPS	$0 ( 2024-02-26 )
Następna data zysków	( $-0.430 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.47
ATR14	$0.225 (2.60%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-02	Gibson Christopher	Sell	21 296	Class B Common Stock
2024-05-01	Gibson Christopher	Sell	25 000	Class A Common Stock
2024-05-01	Gibson Christopher	Sell	50 000	Class A Common Stock
2024-05-02	Gibson Christopher	Buy	21 296	Class A Common Stock
2024-05-02	Gibson Christopher	Sell	21 296	Class A Common Stock

INSIDER POWER
38.37
Last 99 transactions
Buy: 2 817 271 \| Sell: 1 191 870

Wolumen Korelacja

Długi: 0.61 (weak)

Krótki: 0.53 (weak)

Signal:(52) Neutral

Recursion Korelacja

10 Najbardziej pozytywne korelacje
PLXP	0.893
LUMO	0.879
VIRX	0.876
FATE	0.874
STRC	0.867
GROM	0.859
HOOK	0.859
CLEU	0.857
SNCE	0.851
QTEK	0.85

10 Najbardziej negatywne korelacje
XOMAO	-0.832
CCRC	-0.827
XOMAP	-0.825
LUNA	-0.824
ITMR	-0.821
LRFC	-0.821
ACAHU	-0.814
AVEO	-0.813
MICT	-0.813
BNIXU	-0.811

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Recursion Korelacja - Waluta/Towar

0.30
( neutral )

0.77
( moderate )

0.00
( neutral )

0.44
( neutral )

-0.25
( neutral )

-0.06
( neutral )

Recursion Finanse

Annual	2023
Przychody:	$44.58M
Zysk brutto:	$-6.51M (-14.61 %)
EPS:	$-1.580

FY	2023
Przychody:	$44.58M
Zysk brutto:	$-6.51M (-14.61 %)
EPS:	$-1.580

FY	2022
Przychody:	$39.68M
Zysk brutto:	$-8.59M (-21.66 %)
EPS:	$-1.360

FY	2021
Przychody:	$10.18M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.658

Financial Reports:

No articles found.

Recursion

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Aktualne aktualizacje dla Recursion [RXRX]

Upcoming Earnings Alert